Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study von Long, G.V., Flaherty, K.T., Stroyakovskiy, D., Gogas, H., Levchenko, E., de Braud, F., Larkin, J., Garbe, C., Jouary, T., Hauschild, A., Chiarion-Sileni, V., Lebbe, C., Mandalà, M., Millward, M., Arance, A., Bondarenko, I., Haanen, J.B.A.G., Hansson, J., Utikal, J., Ferraresi, V., Mohr, P., Probachai, V., Schadendorf, D., Nathan, P., Robert, C., Ribas, A., Davies, M.A., Lane, S.R., Legos, J.J., Mookerjee, B., Grob, J.-J.

Volltext

Chemotherapy and Targeted Therapy Combinations in Advanced Melanoma von Flaherty, Keith T

Volltext

Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases von Smalley, Keiran S M, Haass, Nikolas K, Brafford, Patricia A, Lioni, Mercedes, Flaherty, Keith T, Herlyn, Meenhard

Volltext

New molecular targets in melanoma von Flaherty, Keith T

Volltext

Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E–mutated melanomas von Smalley, Keiran S M, Lioni, Mercedes, Dalla Palma, Maurizia, Xiao, Min, Desai, Brijal, Egyhazi, Suzanne, Hansson, Johan, Wu, Hong, King, Alastair J, Van Belle, Patricia, Elder, David E, Flaherty, Keith T, Herlyn, Meenhard, Nathanson, Katherine L

Volltext

Mechanisms of Hypertension Associated With BAY 43-9006 von VERONESE, Maria Luisa, MOSENKIS, Ari, FLAHERTY, Keith T, GALLAGHER, Maryann, STEVENSON, James P, TOWNSEND, Raymond R, O'DWYER, Peter J

Volltext

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study von Long, G.V., Flaherty, K.T., Stroyakovskiy, D., Gogas, H., Levchenko, E., de Braud, F., Larkin, J., Garbe, C., Jouary, T., Hauschild, A., Chiarion-Sileni, V., Lebbe, C., Mandalá, M., Millward, M., Arance, A., Bondarenko, I., Haanen, J.B.A.G., Hansson, J., Utikal, J., Ferraresi, V., Mohr, P., Probachai, V., Schadendorf, D., Nathan, P., Robert, C., Ribas, A., Davies, M.A., Lane, S.R., Legos, J.J., Mookerjee, B., Grob, J.-J.

Volltext

PIPELINEs: Creating Comparable Clinical Knowledge Efficiently by Linking Trial Platforms von Trusheim, MR, Shrier, AA, Antonijevic, Z, Beckman, RA, Campbell, RK, Chen, C, Flaherty, KT, Loewy, J, Lacombe, D, Madhavan, S, Selker, HP, Esserman, LJ

Volltext

A Prospective Study of Body Mass Index, Hypertension, and Smoking and the Risk of Renal Cell Carcinoma (United States) von Flaherty, Keith T., Fuchs, Charles S., Colditz, Graham A., Stampfer, Meir J., Speizer, Frank E., Willett, Walter C., Curhan, Gary C.

Volltext

Phase I Trial of Combretastatin A-4 Phosphate with Carboplatin von BILENKER, Joshua H, FLAHERTY, Keith T, SCHNALL, Mitchell, O'DWYER, Peter J, ROSEN, Mark, DAVIS, Lisa, GALLAGHER, Maryann, STEVENSON, James P, WEIJING SUN, VAUGHN, David, GIANTONIO, Bruce, ZIMMER, Ross

Volltext

Biology of advanced uveal melanoma and next steps for clinical therapeutics von Luke, JJ, Triozzi, PL, McKenna, KC, Van Meir, EG, Gershenwald, JE, Bastian, BC, Gutkind, JS, Bowcock, AM, Streicher, HZ, Patel, PM, Sato, T, Sossman, JA, Sznol, M, Welch, J, Thurin, M, Selig, S, Flaherty, KT, Carvajal, RD

Volltext

PCN110 A RETROSPECTIVE CLAIMS DATABASE COMPARISON OF SORAFENIB AND SUNITINIB DOSING PATTERNS IN PATIENTS WITH RENAL CELL CARCINOMA (RCC) von Keefe, S, Moyneur, E, Barghout, V, Flaherty, KT

Volltext

An adaptive signaling network in melanoma inflammatory niches confers tolerance to MAPK signaling inhibition von Young, HL, Rowling, EJ, Bugatti, M, Giurisato, E, Luheshi, N, Arozarena, I, Acosta, JC, Kamarashev, J, Frederick, DT, Cooper, ZA, Reuben, A, Gil, J, Flaherty, KT, Wargo, JA, Vermi, W, Smith, MP, Wellbrock, C, Hurlstone, A

Volltext

A randomized, double-blind, placebo-controlled, phase III study comparing the combination of PDR001, dabrafenib and trametinib versus placebo, dabrafenib and trametinib in previous... von Gasal, E, Fernandez, AMA, Ascierto, PA, Atkinson, V, Dummer, R, Flaherty, KT, Grob, JJ, Hansson, J, Hassel, J, Larkin, J, Lebbe, C, Long, GV, Lorigan, P, Miller, W, Nathan, P, Ribas, A, Robert, C, Schadendorf, D, Tawbi, H, Upalawanna, A

Volltext

Antisense therapeutics: lessons from early clinical trials von Flaherty, Keith T, Stevenson, James P, O'Dwyer, Peter J

Volltext

Innovations and Challenges in Melanoma: Summary Statement from the First Cambridge Conference von Atkins, Michael B, Elder, David E, Essner, Richard, Flaherty, Keith T, Gajewski, Thomas F, Haluska, Frank G, Hwu, Patrick, Keilholz, Ulrich, Kirkwood, John M, Mier, James W, Ross, Merrick I, Slingluff, Craig L, Sondak, Vernon K, Sosman, Jeffrey A, Weinstock, Martin A, King, Laura

Volltext

A phase I, dose escalation trial of ZD0473, a novel platinum analogue, in combination with gemcitabine von FLAHERTY, Keith T, STEVENSON, James P, REDLINGER, Maryann, ALGAZY, Kenneth M, GIANTONIO, Bruce, O'DWYER, Peter J

Volltext

Phase I study of weekly liposome-encapsulated doxorubicin in patients with advanced, androgen-independent prostate cancer von Flaherty, Keith T, Malkowicz, S Bruce, Vaughn, David J

Volltext

Dose escalation study of tezacitabine in combination with cisplatin in patients with advanced cancer von Flaherty, Keith T., Stevenson, James P., Gallagher, Maryann, Giantonio, Bruce, Algazy, Kenneth M., Sun, Weijing, Haller, Daniel G., O'Dwyer, Peter J.

Volltext

Phase I trial of the antifolate ZD9331 in combination with cisplatin in patients with refractory solid malignancies von BILENKER, Joshua H, STEVENSON, James P, FLAHERTY, Keith T, ALGAZY, Kenneth, MCLAUGHLIN, Kathy, HALLER, Daniel G, GIANTONIO, Bruce J, KOEHLER, M, GARCIA-VARGAS, J. E, O'DWYER, Peter J

Volltext